ClinicalTrials.gg
RecruitingNCT06869603Updated Mar 11, 2025

Evaluation of Adherence to the Mediterranean Diet in Patients with Recurrent Renal Stones and Disease Osteometabolic

An observational study in Renal Stones and Osteometabolic Disease, sponsored by IRCCS SYNLAB SDN. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by IRCCS SYNLAB SDN · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this research protocol is to evaluate the adherence to the Mediterranean diet in patients suffering from recurrent kidney stones and osteometabolic diseases. Results of the study will allow to assess the dietary habits of patients with the above diseases. Given the universal prevalence of nephrolithiasis and osteometabolic diseases, the knowledge of these data appears crucial for the proper management of the dietary approach to prophylaxis secondar

02

Conditions studied

  • Renal Stones
  • Osteometabolic Disease

Browse trials for

03

In context

Nephrolithiasis

324 studies on the registry are indexed under Nephrolithiasis; 89 are open to participants now.

This study's planned enrollment of 50 is below the median of 100 across 57 observational studies indexed under Nephrolithiasis.

Browse Nephrolithiasis studies →

Lead sponsor

IRCCS SYNLAB SDN is the lead sponsor of 13 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with idiopathic relapsing nephrolithiasis with evidence instrumental of bilateral renal stones or emission of more than one stone in the past 5 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with idiopathic relapsing nephrolithiasis with evidence instrumental of bilateral renal stones or emission of more than one stone in the past 5 years

Exclusion criteria

Exclusion Criteria:

  • Patients who had albumin-corrected plasma calcium levels > 11.0 mg/dl at the time of the first determination of serum levels of 25 OH vitamin D;
  • Patients who had \< 60 mL/min/1.73 m2;
  • Patients who had positive personal history of chronic granulomatous disease;
  • pregnancy patients;
  • Positive personal history for morphological abnormalities of the excretory system;
  • incomplete data collection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Patient eating habits

    Questionaries to detect the patients eating habits.

    Time frame: 1-36 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 27 observational studies under Nephrolithiasis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 54. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Mar 11, 2025
StartActual
Dec 7, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 2026
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06869603
Lead sponsor
IRCCS SYNLAB SDN
Collaborators
Department of Clinical Medicine and Surgery - University of Naples Federico II
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Dec 7, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion